Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Huvudupphovsmän: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
BMJ Publishing Group
2016
|
Liknande verk
-
Huang Shu Yin funded for further study
av: Kwong Wah, Yit Poh
Publicerad: (2017) -
Huang Shu Yin Funded For Further Study
av: Kwong Wah, Yit Poh
Publicerad: (2017) -
MRE in NAFLD: promising but further validation is required
av: Ryan, J, et al.
Publicerad: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
av: Morrell, L, et al.
Publicerad: (2018) -
Bladder cancer: issues requiring further research
av: I. A. Rozhkov, et al.
Publicerad: (2024-09-01)